World Market for Consumer Health

Delivery

This report comes in PPT.

Key Findings

The industry will have to contend with inflationary pressures and supply disruptions

In 2022, consumer health companies scrambled to adjust to a market environment dominated by shortages in supplies of essential ingredients and materials, severe shipping delays, and the corresponding inflationary pressures that forced them to make difficult decisions on their product portfolios. The industry will likely have to contend with similar dilemmas in 2023.

The results are in: e-commerce is here and only extending its dominance

COVID-19 has sparked a revolution in online shopping for consumer health, and, despite some predictions of a comedown, consumers have sustained and extended interest in purchasing consumer health via e-commerce in 2022. As companies and regulatory regimes adjust, we expect this to continue into the forecast period, especially in long-neglected categories like OTC.

The demand for mental health-orientated products is swelling

Mental health is at the front of every formulator’s mind in 2022, as consumers are loudly demanding solutions to long-unaddressed lifestyle concerns across the mental health spectrum, including stress, anxiety, sleepnessness, and worry. Consumer response is likeliest via partnerships to maximise the gains of pharmacological and behavioural approaches.

How will consumer health companies commercialise holistic health?

Increasingly, consumers demand solutions to a spectrum of considerations and expect them to scale up to a coherent whole that supports their health journeys. Enterprising companies are attacking this problem head-on by taking a page from personalised nutrition and curating an off-the-shelf menu that, combined, will address consumers’ largest needs.

The urgency of coherent women’s health solutions

Organic consumer demand for more robust OTC women’s health solutions has been met in recent months by political events that have only accelerated calls for such action. As a result, it is likely that the forecast period will increasingly see products formulated for health demands across a woman’s lifespan available without a prescription in many markets.

The wave of industry divestments is to continue

The year 2022 has been a banner year for company splits, the primary example being GlaxoSmithKline Plc’s divestment of its consumer health division into stand-alone company, Haleon Plc. The coming years are only going to deepen the industry’s commitment to separating pharmaceutical and consumer divisions, with Johnson & Johnson leading the charge.